、需求向好基本面无虞，坚定看好医药投资机会医药生物-医药生物行业周报证券研究报告/行业周报2024年1月15日评级：增持（维持）[重Ta点bl公e_司Fi基na本nc状e]况分析师：祝嘉琦公司名称股价EPSPEPEG评级执业证书编号：S0740519040001电话：021-20315150智飞生物50.8820222023E2024E2025E20222023E2024E2025E0.51买入Email：zhujq@zts.com.cn天坛生物29.003.143.784.716.0616.2013.4610.808.401.99买入分析师：于佳喜东阿阿胶48.900.531.31买入执业证书编号：S0740523080002健友股份13.581.210.680.831.0154.2442.4835.0128.840.68买入Email：yujx03@zts.com.cn百洋医药33.110.670.79买入美好医疗33.940.961.762.082.5840.3727.8423.5018.921.38买入0.990.680.871.1420.1319.8915.5711.931.271.722.2534.6626.0919....